Get the Stockscreener App
47.43
7.04%
3.12
Pre-market:
47.14
-0.29
-0.61%
Scholar Rock Holding Corp stock is traded at $47.43, with a volume of 3.86M.
It is up +7.04% in the last 24 hours and up +1.28% over the past month.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
See More
Previous Close:
$44.31
Open:
$45.79
24h Volume:
3.86M
Relative Volume:
3.38
Market Cap:
$4.84B
Revenue:
$47.30M
Net Income/Loss:
$-225.97M
P/E Ratio:
-20.18
EPS:
-2.35
Net Cash Flow:
$-188.86M
1W Performance:
+0.98%
1M Performance:
+1.28%
6M Performance:
+46.21%
1Y Performance:
+27.88%
1-Day Range:
$43.59
$48.19
1-Week Range:
$42.07
$48.19
52-Week Range:
$22.71
$49.82
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
47.43 | 4.52B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
Fisher Asset Management LLC Has $19.86 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock at TD Cowen Conference: Strategic Vision and Challenges - Investing.com Nigeria
Piper Sandler raises Scholar Rock stock price target on SMA launch - Investing.com India
SRRK: Citigroup Raises Price Target to $58, Maintains Buy Rating | SRRK Stock News - GuruFocus
Citigroup Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price - MarketBeat
Scholar Rock Holding (SRRK) Sees Price Target Raised by Truist S - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Piper Sandler Raises Price Target for SRRK to $58.00, Maintains Overweight Rating | SRRK Stock News - GuruFocus
Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume Following Earnings Beat - MarketBeat
Barclays Raises Price Target for Scholar Rock Holding (SRRK) to $53 | SRRK Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating - marketscreener.com
Aisling Capital Management LP Takes $2.87 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Decoding Scholar Rock Holding Corp (SRRK): A Strategic SWOT Insi - GuruFocus
SRRK Technical Analysis & ETF Price Forecast - Intellectia AI
Raymond James Maintains Strong Buy on Scholar Rock (SRRK) Mar 2026 - Meyka
Scholar Rock (NASDAQ: SRRK) posts 2025 loss, expands debt capacity - Stock Titan
Barclays raises Scholar Rock stock price target to $53 on debt deal - Investing.com
Scholar Rock (SRRK) Revises Financial Results for Q4 2025 - GuruFocus
Truist raises Scholar Rock stock price target on manufacturing progress By Investing.com - Investing.com Australia
Truist raises Scholar Rock stock price target on manufacturing progress - Investing.com
Raymond James reiterates Scholar Rock stock Strong Buy on debt facility - Investing.com
Scholar Rock Q4 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Gap UpTime to Buy? - MarketBeat
Scholar Rock Q4 2025 Earnings Call Transcript - MarketBeat
Scholar Rock Holding (SRRK) Receives Reiterated 'Buy' Rating fro - GuruFocus
Scholar Rock (NASDAQ:SRRK) Given Buy Rating at HC Wainwright - MarketBeat
Scholar Rock Holding Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Scholar Rock Q4 2025 shows slight EPS beat, stock rises - Investing.com
Scholar Rock (SRRK) Q4 2025 Earnings Transcript - AOL.com
Scholar Rock Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Scholar Rock (SRRK) Poised for FDA Resubmission of Apitegromab - GuruFocus
Vanguard Group Inc. Has $183.03 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (NASDAQ:SRRK) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 - ChartMill
Scholar Rock FY income from operations USD -384.645 million - marketscreener.com
Scholar Rock Advances Apitegromab Toward SMA Commercial Launch - TipRanks
Scholar Rock (SRRK) 2025 loss widens as SMA programs advance - Stock Titan
Scholar Rock Holding 10-K: Operating loss $384.6M, Net loss $377.9M - TradingView
Scholar Rock Q4 Net Loss Widens - marketscreener.com
SRRKForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Earnings Flash (SRRK) Scholar Rock Posts Q4 Net Loss $0.88 a Share, vs. FactSet Est of $0.89 Loss - marketscreener.com
Apitegromab and SRK-439 lead Scholar Rock (NASDAQ: SRRK) neuromuscular pipeline - Stock Titan
Scholar Rock Holding: Q4 Earnings Insights - Benzinga
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Stock Titan
Scholar Rock Holding Corporation $SRRK Shares Purchased by Rafferty Asset Management LLC - MarketBeat
SRRK Earnings History & Surprises | EPS & Revenue Results | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock investors brace for earnings amid FDA resubmission push By Investing.com - Investing.com UK
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):